Fortress Biotech Inc. (FBIO)
1.64
-0.01 (-0.61%)
At close: Feb 20, 2025, 3:59 PM
1.63
-0.31%
After-hours: Feb 20, 2025, 04:37 PM EST
undefined% (undefined)
| Bid | 1.62 |
| Market Cap | 45.13M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.96 |
| PE Ratio (ttm) | -0.55 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.71 |
| Volume | 217,015 |
| Avg. Volume (20D) | 547,652 |
| Open | 1.63 |
| Previous Close | 1.65 |
| Day's Range | 1.60 - 1.65 |
| 52-Week Range | 1.36 - 2.89 |
| Beta | undefined |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2011
Employees 186
Stock Exchange NASDAQ
Ticker Symbol FBIO
Website https://www.fortressbiotech.com
Analyst Forecast
According to 3 analyst ratings, the average rating for FBIO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 1000.92% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Fortress Biotech Inc. is scheduled to release its earnings on Mar 27, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
-18.48%
Fortress Biotech shares are trading lower after th...
Unlock content with
Pro Subscription
7 months ago
Fortress Biotech shares are trading lower after the company announced a pause in the payment of dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.
